Similarly, in the CORALLEEN trial (40), the combination of another CDK4/6 inhibitor (Ribociclib) with letrozole was found to be more effective than chemotherapy in downstaging high-risk luminal B breast cancer. This evidence concerns the gene CDK4 and breast cancer.